platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control excessive bleeding following traumatic injury, or in individuals with impaired clotting due to an inherited condition or as a result of certain medications or chemotherapy.
wearable sensors, Verizon, fitness trackers, smart watches

Wearable sensors are expected to play a big role in healthcare in the coming years, according to Verizon, as data from these devices are integrated into patient electronic medical records. They offer a big-picture view of a patient's health, beyond a yearly checkup. These devices are also expected to play a major role as healthcare organizations look for new ways to engage patients electronically to meet new federal health IT requirements.

Opsens Inc. announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the OptoWire and OptoMonitor, its products developed to measure fractional flow reserve (FFR). This measure is used to optimize the diagnostic and guide the treatment of patients with coronary heart disease.

The Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA) announced efforts to help physicians prepare for the nationwide switch from ICD-9 to ICD-10 ahead of the October 1 deadline. In response to requests from the provider community, CMS is releasing additional guidance that will allow for flexibility in the claims auditing and quality reporting process as the medical community gains experience using the new ICD-10 code set for medical diagnoses and inpatient hospital procedures.

Health data security and patient engagement are top priorities for the nation's hospitals, according to results of the 17th annual HealthCare's Most Wired Survey. The annual survey was released by the American Hospital Association's Health Forum and the College of Healthcare Information Management Executives (CHIME).

St. Jude Medical, OCT, ILUMIEN III, IVUS, angiography, PCI

St. Jude Medical, Inc. announced the launch of the ILUMIEN III clinical trial on June 30. ILUMIEN III is a prospective, international, randomized trial evaluating the clinical benefits of the company's optical coherence tomography (OCT) guidance during stent implantation. The study will compare OCT-guided stent implantation to implantation guided by intravascular ultrasound (IVUS) or angiography alone, diagnostic tools that offer less resolution than OCT during intravascular assessments and percutaneous coronary intervention (PCI).
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now